SCHEMBL27426293

SCHEMBL27426293

Cc1cc([C@H]2Oc3c(c(O)cc(O)c3[C@H]3C[C@@H](c4ccc(O)cc4)Oc4cc(O)ccc43)C[C@@H]2O)ccc1O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VEGFA P15692 3/20 0.68
PGF P49763 3/20 0.68
FLT1 P17948 2/20 0.68
PTGS1 P23219 3/20 0.51
SNCA P37840 3/20 0.49
HSD17B10 Q99714 3/20 0.49
CYP1A2 P05177 1/20 0.49
ALOX15 P16050 1/20 0.49
MMP2 P08253 4/20 0.48
MMP9 P14780 4/20 0.48
PRKD3 O94806 1/20 0.48
PRKCG P05129 1/20 0.48
PRKCB P05771 1/20 0.48
PRKCA P17252 1/20 0.48
PRKCH P24723 1/20 0.48
PRKCI P41743 1/20 0.48
PRKCE Q02156 1/20 0.48
PRKCQ Q04759 1/20 0.48
PRKCZ Q05513 1/20 0.48
PRKCD Q05655 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27426284 0.92 VEGFA (0.71) VEGFAPGFFLT1PTGS1SNCA
SCHEMBL27426382 0.92 VEGFA (0.71) VEGFAPGFFLT1PTGS1SNCA
SCHEMBL27426404 0.92 VEGFA (0.71) VEGFAPGFFLT1PTGS1SNCA
SCHEMBL27426399 0.89 VEGFA (0.67) VEGFAPGFFLT1PTGS1SNCA
SCHEMBL27426275 0.89 VEGFA (0.67) VEGFAPGFFLT1PTGS1SNCA
SCHEMBL27426290 0.89 VEGFA (0.67) VEGFAPGFFLT1PTGS1SNCA
SCHEMBL27426577 0.89 VEGFA (0.67) VEGFAPGFFLT1PTGS1SNCA
SCHEMBL27426375 0.89 VEGFA (0.67) VEGFAPGFFLT1PTGS1SNCA
SCHEMBL18293074 0.78 VEGFA (0.81) VEGFAPGFFLT1PTGS1SNCA
SCHEMBL25736035 0.73 SNCA (0.89) VEGFAPGFPTGS1SNCAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216458-A1 Composition for the prevention, improvement or treatment of allergic diseases comprising an extract of Cassia mimosoides L. as an active ingredient KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2024-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216458-A1 Composition for the prevention, improvement or treatment of allergic diseases comprising an extract of Cassia mimosoides L. as an active ingredient CMA1, HRH4, CCL11 VEGFA 2250/4885PGF 3791/4885FLT1 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.